National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Pegaspargase (Oncaspar®) powder for solution for injection/infusion is indicated as a component of antineoplastic combination therapy in acute lymphoblastic leukaemia in paediatric patients from birth to 18 years.

NCPE Assessment Process Complete
Rapid Review commissioned 05 February 2020
Rapid Review completed 13 March 2020
Rapid Review Outcome A full HTA is not recommended. The NCPE recommends that pegaspargase (Oncaspar®) be considered for reimbursement*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.